MIODx was founded in 2014 with the belief that the current methods of monitoring cancer progression are still lacking. We believe a better cancer therapy begins with a better diagnostic, and the one-size fits all approach used today, doesn't work when dealing with a hyperdynamic biological system.
To give a better diagnosis, you need to have the best information possible. To accomplish this goal, we began our journey to discover the best platform to monitor a patient's immune response. Working with leaders in the field of immunotherapy, oncology, genetics, and immunosequencing we constantly explore the amalgamation of biology, software and engineering.